Vaccine volunteer died of poisoning: Bharat Biotech


Bharat Biotech International limited has in a statement issued Saturday said the probable cause of death of a volunteer in Phase III trials was cardio respiratory failure as a result of suspected poisoning. The firm said the case is under police investigation.

“We would like to state that a volunteer passed away on December 21, 2020 and the death was reported to the People’s College of Medical Sciences & Research Centre by the son of the deceased. The volunteer, at the time of enrolment, had fulfilled all the inclusion and exclusion criteria to be accepted as a participant in the Phase III trial and was reported to be healthy in all the site follow up calls post 7 days of his dosing and no adverse events were observed or reported. The volunteer passed away nine days after the dosing and preliminary reviews by the site indicate that the death is unrelated to the study dosing,” BBIL officials said, quoting the postmortem report.

The company said it cannot confirm if the volunteer received the study vaccine or a placebo as the study is blinded.

The Drug Controller General of India (DCGI) recently approved the emergency use of Oxford-AstraZeneca’s Covishield and indigenously developed Covaxin of Bharat Biotech for immunisation against Covid-19 in India. The country will kick off the vaccination drive against Covid-19 on January 16.

In accordance with the provisions of the New Drugs & Clinical Trials Rules, (NDCT rules 2019) the serious adverse event was reported by the site team to the Institutional Ethics Committee, the Central Drugs Control Standards Organization (CDSCO) and the Data Safety Monitoring Board (DSMB) in accordance to all the required guidelines. There are several factors that can cause an adverse event during a clinical trial, including the patient’s underlying disease, other pre-existing conditions or any other unrelated occurrence like an accident. The NDCT rules mandate that all adverse events (AE) and serious adverse events (SAE) be reported, whether related to the trial medication or not, officials said

This serious adverse event has been thoroughly investigated and has been found not related to vaccine or placebo, the statement said. “All data and reports on this has been submitted to the Site Ethics Committee, CDSCO and DSMB. We are also continuing to cooperate with the investigation requirements from the Madhya Pradesh Police in Bhopal,” the statement added.

The officials expressed their sympathy with the family of the deceased. “However, we would like to reiterate that we conduct our clinical trials in compliance with the study protocol, Good Clinical Practices (GCP) Guidelines as well as with all applicable statutory provisions and the focus at all times is on patient safety. It is this intent on compliance, quality and ethics, that we have enlisted the services of an international contract research organization to conduct our phase III clinical trials,” the statement added.

Source link


Please enter your comment!
Please enter your name here